PMID- 34983249
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220303
IS  - 1461-7285 (Electronic)
IS  - 0269-8811 (Linking)
VI  - 36
IP  - 1
DP  - 2022 Jan
TI  - MDMA/ecstasy use and psilocybin use are associated with lowered odds of 
      psychological distress and suicidal thoughts in a sample of US adults.
PG  - 46-56
LID - 10.1177/02698811211058923 [doi]
AB  - BACKGROUND: Suicide is one of the leading causes of death worldwide and rates 
      within the United States have risen over the past two decades. Hence, there is a 
      critical need for novel tools to treat suicidal ideation and related mental 
      health conditions. 3,4-Methylenedioxymethamphetamine (MDMA)/ecstasy and classic 
      psychedelics may be two such tools. AIMS: The aim of this study was to assess 
      non-causal associations between MDMA/ecstasy and classic psychedelic use and 
      psychological distress and suicide risk. METHODS: In this study, we examined the 
      aforementioned associations among 484,732 adult participants in the National 
      Survey on Drug Use and Health (2008-2019). RESULTS: Lifetime MDMA/ecstasy use was 
      associated with reduced odds of past year suicidal thinking (10% reduced odds; 
      odds ratio (OR) = 0.90; 95% confidence interval, CI = (0.84-0.97); p < 0.01) and 
      past year suicidal planning (OR = 0.88; 95% CI = (0.78-0.99); p < 0.05). 
      Furthermore, lifetime psilocybin use was associated with reduced odds of past 
      month psychological distress (OR = 0.78; 95% CI = (0.73-0.84); p < 0.001) and 
      past year suicidal thinking (OR = 0.90; 95% CI = (0.83-0.96); p < 0.01). Finally, 
      lysergic acid diethylamide (LSD) was associated with increased odds of past year 
      suicidal thinking (OR = 1.07; 95% CI = (1.00-1.15); p < 0.05). CONCLUSION: 
      MDMA/ecstasy and psilocybin use are associated with reduced odds of suicidal 
      thinking and related outcomes-though experimental studies are needed to determine 
      whether these associations are causal. These findings call for more research into 
      the efficacy of MDMA/ecstasy and classic psychedelics for treating psychological 
      distress and suicidal thoughts and behaviors, and for updated drug legislation 
      that allows for further investigation into these substances.
FAU - Jones, Grant M
AU  - Jones GM
AUID- ORCID: 0000-0002-2426-310X
AD  - Department of Psychology, Harvard University, Cambridge, MA, USA.
FAU - Nock, Matthew K
AU  - Nock MK
AD  - Department of Psychology, Harvard University, Cambridge, MA, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20220105
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - 0 (Hallucinogens)
RN  - 2RV7212BP0 (Psilocybin)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Hallucinogens/administration & dosage/pharmacology
MH  - Health Surveys
MH  - Humans
MH  - Lysergic Acid Diethylamide/administration & dosage/pharmacology
MH  - Male
MH  - Middle Aged
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*pharmacology
MH  - Psilocybin/administration & dosage/*pharmacology
MH  - Stress, Psychological/*psychology
MH  - Substance-Related Disorders/epidemiology/psychology
MH  - *Suicidal Ideation
MH  - United States
MH  - Young Adult
OTO - NOTNLM
OT  - Ecstasy
OT  - LSD
OT  - MDMA
OT  - NSDUH
OT  - psilocybin
OT  - psychedelics
OT  - suicide
EDAT- 2022/01/06 06:00
MHDA- 2022/03/04 06:00
CRDT- 2022/01/05 05:27
PHST- 2022/01/06 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2022/01/05 05:27 [entrez]
AID - 10.1177/02698811211058923 [doi]
PST - ppublish
SO  - J Psychopharmacol. 2022 Jan;36(1):46-56. doi: 10.1177/02698811211058923. Epub 
      2022 Jan 5.